We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
FDA Confirms Positive Safety Profile of Acadia's Nuplazid
Read MoreHide Full Article
Shares of ACADIA Pharmaceuticals Inc. (ACAD - Free Report) soared 26.6% after the FDAissued a clear statement reaffirming the positive benefit-risk profile of Nuplazid (pimavanserin) for patients with Parkinson’s disease psychosis. However, shares of the company have decreased 36.5% year to date compared with the industry’s decline of 3.5%.
Nuplazid was approved by the FDA in April 2016 for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis, (PDP). It is the only drug approved in the United States for this indication. The approval was supported by a phase III study that demonstrated clinically robust and highly statistically significant efficacy, combined with other supportive studies.
There were reports of deaths and serious adverse events (SAEs) with the use of Nuplazid. However, based on post-marketing reports, the FDA concluded that it did not identify any new or unexpected safety findings with Nuplazid, or findings that are inconsistent with the established safety profile currently described in the drug label.
The agency stated that the drug’s benefits outweigh its risks for patients with hallucinations and delusions of Parkinson’s disease psychosis. The FDA said that Nuplazid and other antipsychotics already have warnings on their boxes, indicating a higher risk of death in elderly patients with the use of such drugs.
According to the agency, individuals with Parkinson's disease psychosis are more at risk of death due to their age, disease and other medical conditions. The FDA further added that patients taking Nuplazid for Parkinson’s disease psychosis should continue to use it as prescribed by their health care provider.
The FDA, however, reminded the health care providers to be aware of the risks described in the prescribing information.
Sales of Nuplazid increased 87% in the second quarter.
Gilead’s earnings per share estimates have increased from $6.15 to $6.58 for 2018 and from $6.33 to $6.48 for 2019 over the past 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters with an average beat of 6.43%. The stock has rallied 4.5% so far this year.
Regeneron’s earnings per share estimates have increased from $20.20 to $20.38 for 2018 and from $21.65 to $21.74 for 2019 over the past 30 days. The company delivered a positive earnings surprise in all of the trailing four quarters with an average beat of 8.18%. The stock has rallied 3.0% so far this year.
Ligand’s earnings per share estimates have moved up from $5.64 to $6.33 for 2018 and from $5.59 to $5.74 for 2019 in the last 30 days. The company delivered a positive earnings surprise in all of the trailing four quarters with an average beat of 59.54%. Share price of the company has increased 88.3% year to date.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
FDA Confirms Positive Safety Profile of Acadia's Nuplazid
Shares of ACADIA Pharmaceuticals Inc. (ACAD - Free Report) soared 26.6% after the FDAissued a clear statement reaffirming the positive benefit-risk profile of Nuplazid (pimavanserin) for patients with Parkinson’s disease psychosis. However, shares of the company have decreased 36.5% year to date compared with the industry’s decline of 3.5%.
Nuplazid was approved by the FDA in April 2016 for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis, (PDP). It is the only drug approved in the United States for this indication. The approval was supported by a phase III study that demonstrated clinically robust and highly statistically significant efficacy, combined with other supportive studies.
There were reports of deaths and serious adverse events (SAEs) with the use of Nuplazid. However, based on post-marketing reports, the FDA concluded that it did not identify any new or unexpected safety findings with Nuplazid, or findings that are inconsistent with the established safety profile currently described in the drug label.
The agency stated that the drug’s benefits outweigh its risks for patients with hallucinations and delusions of Parkinson’s disease psychosis. The FDA said that Nuplazid and other antipsychotics already have warnings on their boxes, indicating a higher risk of death in elderly patients with the use of such drugs.
According to the agency, individuals with Parkinson's disease psychosis are more at risk of death due to their age, disease and other medical conditions. The FDA further added that patients taking Nuplazid for Parkinson’s disease psychosis should continue to use it as prescribed by their health care provider.
The FDA, however, reminded the health care providers to be aware of the risks described in the prescribing information.
Sales of Nuplazid increased 87% in the second quarter.
ACADIA Pharmaceuticals Inc. Price
ACADIA Pharmaceuticals Inc. Price | ACADIA Pharmaceuticals Inc. Quote
Zacks Rank & Stocks to Consider
Acadia is a Zacks Rank #4 (Sell) stock.
Some better-ranked stocks in the biotech sector are Gilead Sciences Inc. (GILD - Free Report) , Regeneron Pharmaceuticals Inc. (REGN - Free Report) and Ligand Pharmaceuticals Inc. (LGND - Free Report) . All of them carry a Zacks Rank #1 (Strong Buy).You can see the complete list of today’s Zacks #1 Rank stocks here.
Gilead’s earnings per share estimates have increased from $6.15 to $6.58 for 2018 and from $6.33 to $6.48 for 2019 over the past 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters with an average beat of 6.43%. The stock has rallied 4.5% so far this year.
Regeneron’s earnings per share estimates have increased from $20.20 to $20.38 for 2018 and from $21.65 to $21.74 for 2019 over the past 30 days. The company delivered a positive earnings surprise in all of the trailing four quarters with an average beat of 8.18%. The stock has rallied 3.0% so far this year.
Ligand’s earnings per share estimates have moved up from $5.64 to $6.33 for 2018 and from $5.59 to $5.74 for 2019 in the last 30 days. The company delivered a positive earnings surprise in all of the trailing four quarters with an average beat of 59.54%. Share price of the company has increased 88.3% year to date.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>